Health
Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
PRINCETON, N.J., December 08, 2025--Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/b381d0fb57aa22e11717075aa3c7b1ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xPXlZwEioLggcZlLzrC_mg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b381d0fb57aa22e11717075aa3c7b1ec","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/IQH2bEeulJtSn_h_Q3BNsA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/b381d0fb57aa22e11717075aa3c7b1ec","width":1200,"height":165}},"lazy":false},{"type":"text","content":"PRINCETON, N.J., December 08, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting.","length":261,"tagName":"p"},{"type":"text","content":"Highlights include updates from the company’s targeted protein degradation pipeline, including data on first-in-class investigational lymphoma CELMoD™ agent golcadomide and first-in-class BCL6 ligand-directed degrader BMS-986458; alongside long-term results for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, from the Phase 3 TRANSFORM and Phase 2 TRANSCEND FL trials.","length":433,"tagName":"p"},{"type":"text","content":""The data presented at ASH represent a significant step forward in our pursuit of transformative outcomes for patients with lymphoma, who urgently need more effective and durable treatment options," said Anne Kerber, senior vice president, head of development, Hematology, Oncology and Cell Therapy, Bristol Myers Squibb. "From the potential of golcadomide to offer meaningful benefit in aggressive B-cell and follicular lymphomas, to the innovative mechanism of our BCL6 ligand-directed degrader, BMS-986458, and the proven, long-term efficacy of Breyanzi – these collective results underscore our dedication to pioneering therapies that make a real difference for patients."","length":696,"tagName":"p"},{"type":"text","content":"Targeted Protein Degradation","length":28,"tagName":"p"},{"type":"te...